214 related articles for article (PubMed ID: 31434944)
41. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
Vaxman I; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Kapoor P; Grogan M; Go R; Lin Y; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Gertz MA; Dispenzieri A
Leukemia; 2021 Dec; 35(12):3604-3607. PubMed ID: 34021252
[No Abstract] [Full Text] [Related]
42. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure.
Aimo A; Januzzi JL; Mueller C; Mirò O; Pascual Figal DA; Jacob J; Herrero-Puente P; Llorens P; Wussler D; Kozhuharov N; Sabti Z; Breidthardt T; Vergaro G; Ripoli A; Prontera C; Saccaro L; Passino C; Emdin M
Int J Cardiol; 2019 Oct; 293():137-142. PubMed ID: 31200964
[TBL] [Abstract][Full Text] [Related]
43. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19.
Myhre PL; Prebensen C; Strand H; Røysland R; Jonassen CM; Rangberg A; Sørensen V; Søvik S; Røsjø H; Svensson M; Berdal JE; Omland T
Circulation; 2020 Dec; 142(22):2128-2137. PubMed ID: 33058695
[TBL] [Abstract][Full Text] [Related]
44. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
46. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
47. Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome.
Aimo A; Januzzi JL; Vergaro G; Clerico A; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Ueland T; Nymo SH; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Ripoli A; Passino C; Emdin M
Eur J Prev Cardiol; 2019 Nov; 26(16):1751-1759. PubMed ID: 31154828
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide.
Jin XL; Huang N; Shang H; Zhou MC; Hong Y; Cai WZ; Huang J
J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28719009
[TBL] [Abstract][Full Text] [Related]
49. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
[TBL] [Abstract][Full Text] [Related]
50. The prognostic values of GDF-15 in comparison with NT-proBNP in patients with normotensive acute pulmonary embolism.
Duran L; Kayhan S; Guzel A; Ince M; Kati C; Akdemir HU; Yavuz Y; Zengin H; Okuyucu A; Murat N
Clin Lab; 2014; 60(8):1365-71. PubMed ID: 25185423
[TBL] [Abstract][Full Text] [Related]
51. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
52. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
Lichtenauer M; Jirak P; Wernly B; Paar V; Rohm I; Jung C; Schernthaner C; Kraus J; Motloch LJ; Yilmaz A; Hoppe UC; Christian Schulze P; Kretzschmar D; Pistulli R
Eur J Intern Med; 2017 Oct; 44():31-38. PubMed ID: 28579310
[TBL] [Abstract][Full Text] [Related]
53. Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis.
Cappelli F; Baldasseroni S; Bergesio F; Padeletti L; Attanà P; Pignone AM; Grifoni E; Ciuti G; Fabbri A; Tarantini F; Marchionni N; Gensini GF; Perfetto F
Amyloid; 2014 Jun; 21(2):97-102. PubMed ID: 24517408
[TBL] [Abstract][Full Text] [Related]
54. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.
Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Rocca HB; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Wilson Tang WH; Grodin JL; Passino C; Emdin M
Int J Cardiol; 2019 Feb; 277():166-172. PubMed ID: 30416028
[TBL] [Abstract][Full Text] [Related]
55. The Role of Biomarkers in Predicting Cognitive Impairment in Elderly Patients with Heart Failure.
Arslan A; Çelik A; Döven O
Turk Kardiyol Dern Ars; 2024 Jun; 52(4):244-252. PubMed ID: 38829644
[TBL] [Abstract][Full Text] [Related]
56. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
Lindholm D; James SK; Bertilsson M; Becker RC; Cannon CP; Giannitsis E; Harrington RA; Himmelmann A; Kontny F; Siegbahn A; Steg PG; Storey RF; Velders MA; Weaver WD; Wallentin L;
Clin Chem; 2017 Feb; 63(2):573-584. PubMed ID: 27932413
[TBL] [Abstract][Full Text] [Related]
57. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
58. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients.
Heringlake M; Charitos EI; Gatz N; Käbler JH; Beilharz A; Holz D; Schön J; Paarmann H; Petersen M; Hanke T
J Am Coll Cardiol; 2013 Feb; 61(6):672-81. PubMed ID: 23391200
[TBL] [Abstract][Full Text] [Related]
59. Variability of biomarkers in patients with chronic heart failure and healthy controls.
Meijers WC; van der Velde AR; Muller Kobold AC; Dijck-Brouwer J; Wu AH; Jaffe A; de Boer RA
Eur J Heart Fail; 2017 Mar; 19(3):357-365. PubMed ID: 27766733
[TBL] [Abstract][Full Text] [Related]
60. Impaired right ventricular function as a predictor of early mortality in patients with light‑ chain cardiac amyloidosis assessed in a cardiology department.
Szczygieł JA; Wieczorek PZ; Drozd-Sokołowska J; Michałek P; Mazurkiewicz Ł; Legatowicz-Koprowska M; Walczak E; Jędrzejczak WW; Dwilewicz-Trojaczek J; Grzybowski J
Pol Arch Intern Med; 2017 Dec; 127(12):854-864. PubMed ID: 29112180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
